Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:chemical_compound |
| gptkbp:administeredBy |
oral medication
|
| gptkbp:CASNumber |
1202036-66-1
|
| gptkbp:developedBy |
gptkb:Mirati_Therapeutics
|
| gptkbp:hasMolecularFormula |
C38H41N7O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sitravatinib
|
| gptkbp:IUPACName |
6-(6,7-dimethoxyquinolin-4-yl)-N-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]imidazo[1,2-b]pyridazin-2-amine
|
| gptkbp:mechanismOfAction |
multi-kinase inhibition
|
| gptkbp:phase_of_clinical_trials |
Phase 3 (as of 2023)
|
| gptkbp:PubChem_CID |
71288861
CHEMBL3544940 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:VEGFR
gptkb:AXL gptkb:MET TAM family kinases |
| gptkbp:UNII |
6Q6K1T4F1F
|
| gptkbp:used_in_clinical_trials_for |
gptkb:non-small_cell_lung_cancer
renal cell carcinoma |
| gptkbp:bfsParent |
gptkb:Mirati_Therapeutics
|
| gptkbp:bfsLayer |
7
|